Back to Browse Journals » Research and Reports in Urology » Volume 3

Sipuleucel-T: immunotherapy for advanced prostate cancer

Authors Olson BM, McNeel DG

Published Date May 2011 Volume 2011:3 Pages 49—60


Published 3 May 2011

Brian M Olson, Douglas G McNeel
University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA
Abstract: Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being associated with potentially significant side effects. However, the recent approval of sipuleucel-T has given patients with advanced disease an additional treatment option that has demonstrated benefit without the side effects associated with chemotherapy. Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient's own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer. Specifically, we present some of the issues associated with the management of advanced prostate cancer, the research and development that led to the approval of sipuleucel-T, how the approval of sipuleucel-T could change the clinical management of prostate cancer, and current and future areas of investigation that are being pursued with regard to sipuleucel-T and other treatments for advanced prostate cancer.

Keywords: sipuleucel-T, prostatic acid phosphatase, granulocyte-macrophage colonystimulating factor

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Toxicology of antimicrobial nanoparticlesfor prosthetic devices

Nuñez-Anita RE, Acosta-Torres LS, Vilar-Pineda J, Martínez-Espinosa JC, de la Fuente-Hernández J, Castaño VM

International Journal of Nanomedicine 2014, 9:3999-4006

Published Date: 20 August 2014

Ovarian cancer biomarkers as diagnostic triage tests

Jordan SM, Bristow RE

Current Biomarker Findings 2013, 3:35-42

Published Date: 25 February 2013

PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses

Ma W, Chen M, Kaushal S, McElroy M, Zhang Y, Ozkan C, Bouvet M, Kruse C, Grotjahn D, Ichim T, Minev B

International Journal of Nanomedicine 2012, 7:1475-1487

Published Date: 15 March 2012

Poor physical function in elderly women in low-level aged care is related to muscle strength rather than to measures of sarcopenia

Julie L Woods, Sandra Iuliano-Burns, Susannah J King, et al

Clinical Interventions in Aging 2011, 6:67-76

Published Date: 23 March 2011

Social determinants in ocular diseases

Reza Gharebaghi, Fatemeh Heidary, Roghayeh Heidary, et al 

Clinical Optometry 2010, 2:119-120

Published Date: 6 December 2010

Characterization of electrospun nanocomposite scaffolds and biocompatibility with adipose-derived human mesenchymal stem cells

Seth D McCullen, Derrick R Stevens, Wesley A Roberts, Laura I Clarke, Susan H Bernacki,
Russell E Gorga, Elizabeth G Loboa

International Journal of Nanomedicine 2007, 2:253-263

Published Date: 16 August 2007

Selective placement of templated DNA nanowires between microstructured electrodes

Joseph M Kinsella, Albena Ivanisevic

International Journal of Nanomedicine 2006, 1:219-222

Published Date: 25 January 2006